Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Next Previous
Trial Profile

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPARZ
  • Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 06 Jun 2023 Results of post hoc analysis of COMPARZ study short- and long-term hepatorenal toxicity differences between pazopanib and sunitinib, and to explore the factors predisposing to hepatorenal toxicity assessing presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results of post-hoc analysis assessing novel prognostic model for oligometastatic renal cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2022 Samples from COMPARZ and IMmotion 150 assessing the relation between FOLH1 expression and angiogenesis, as well as clinical outcomes presented at the 117th Annual Meeting of the American Urological Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top